In another preclinical investigation, the combination of angiogenesis inhibitors (which block the VEGF signaling pathway) and AZD3965 decreases tumor development while simultaneously decreasing both hypoxia and blood perfusion in tumor tissues (49). Here, VEGFA is linked to neoplasm.